16 CHAPTER 1 REFERENCES 1. American Cancer Society. Cancer Facts & Figures 2022. 2. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca-Cancer J Clin 2021;71(3):209-249. (In English). DOI: 10.3322/caac.21660. 3. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell 2011;144(5):646-674. (In English). DOI: 10.1016/j.cell.2011.02.013. 4. Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov 2022;12(1):31-46. (In English). DOI: 10.1158/2159-8290.Cd-21-1059. 5. Hajdu SI. 2000 years of chemotherapy of tumors. Cancer-Am Cancer Soc 2005;103(6):1097-1102. (In English). DOI: 10.1002/cncr.20908. 6. DeVita VT, Chu E. A History of Cancer Chemotherapy. Cancer Research 2008;68(21):8643-8653. (In English). DOI: 10.1158/0008-5472.Can-07-6611. 7. Santucci C, Carioli G, Bertuccio P, et al. Progress in cancer mortality, incidence, and survival: a global overview. Eur J Cancer Prev 2020;29(5):367-381. (In English). DOI: 10.1097/Cej.0000000000000594. 8. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New Engl J Med 2019;381(16):1535-1546. (In English). DOI: 10.1056/NEJMoa1910836. 9. Larkin J, Ascierto PA, Dreno B, et al. Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma. New Engl J Med 2014;371(20):1867-1876. (In English). DOI: 10.1056/NEJMoa1408868. 10. Ziogas DC, Konstantinou F, Bouros S, Theochari M, Gogas H. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma. Am J Clin Dermatol 2021;22(3):301-314. (In English). DOI: 10.1007/s40257-021-00593-9. 11. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000;6:S55-S57. (In English) (<Go to ISI>:// WOS:000085283900012). 12. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 2005;23(1):133-141. (In English). DOI: 10.1200/Jco.2005.03.206. 13. Motzer RJ, Murphy BA, Bacik J, et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. Journal of Clinical Oncology 2000;18(16):29722980. (In English). DOI: Doi 10.1200/Jco.2000.18.16.2972. 14. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. New Engl J Med 1998;338(18):1272-1278. (In English). DOI: Doi 10.1056/Nejm199804303381805.
RkJQdWJsaXNoZXIy MTk4NDMw